Brief: Aptose Presents Early Phase 1A/B CG-806 Clinical Findings
12/06/2020 12:13
June 12 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE PRESENTS EARLY PHASE 1A/B CG-806 CLINICAL FINDINGS
AT THE
25TH CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION
* APTOSE BIOSCIENCES - CG-806 WAS WELL-TOLERATED IN PATIENTS
TREATED AT 150MG, 300MG AND 450MG BID OVER MULTIPLE CYCLES
* APTOSE BIOSCIENCES- NEW IND SUBMITTED TO BEGIN TESTING
CG-806 IN
AML PATIENTS
Source text for Eikon: ID:nGNXc2KYd7
Further company coverage: APS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting